Exosomes vs PRP
A Clinician's Comparison

Why Practitioners Are Asking This Question

Platelet-rich plasma has been used in clinical settings for decades. It has a well-documented procedural track record in orthopedics, sports medicine, and aesthetic medicine, along with a familiar procurement and preparation workflow. MSC-derived exosomes are newer, with a rapidly expanding research base and a fundamentally different biological profile.

As exosomes become more widely available through wholesale suppliers, licensed practitioners are increasingly asked to evaluate them alongside PRP in the context of their existing practice. The question is not usually "which is better" but rather: what are these products, how do they differ biologically, what does the research say, and what are the regulatory and procurement implications of each?

This article addresses those questions. It does not recommend one product over the other, does not make therapeutic claims for either, and does not substitute for legal or regulatory counsel regarding specific clinical use.

What PRP Is and How It Is Prepared

Platelet-rich plasma is prepared by drawing a volume of the patient's own blood, separating the cellular components by centrifugation, and concentrating the platelet fraction into a smaller plasma volume. The result is an autologous preparation with a higher platelet concentration than whole blood, typically 2 to 7 times baseline depending on the preparation system used.

Platelets are not inert clotting agents. They contain alpha granules packed with growth factors including platelet-derived growth factor (PDGF), transforming growth factor beta (TGF-beta), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), and insulin-like growth factor (IGF-1). When activated, platelets release these factors into the surrounding tissue environment. A 2018 review published in Plastic and Reconstructive Surgery describes this growth factor release as the primary proposed mechanism through which PRP may influence tissue biology.[3]

Because PRP is autologous, it avoids the immunogenic risks associated with allogeneic products. Its composition varies meaningfully between patients, between preparation systems, and even between sessions for the same patient. This variability is one of the most significant challenges in PRP research, making standardized clinical conclusions difficult to draw.

What MSC-Derived Exosomes Are and How They Are Produced

MSC-derived exosomes are small extracellular vesicles, typically 30 to 150 nanometers in diameter, secreted by mesenchymal stem cells during cell culture. They are collected from conditioned media, purified, characterized, and prepared for storage and distribution. The production process is entirely ex vivo and involves no patient blood draw.

Unlike PRP, exosomes are allogeneic: they originate from donor cells, not the patient receiving them. This means the product can be manufactured at scale, characterized to a defined standard, and supplied in a consistent lot-controlled format. A 2024 review in Signal Transduction and Targeted Therapy identifies consistent lot characterization as one of the practical advantages of exosomes over live cell therapies, noting defined particle concentration, size distribution, and surface marker profiles as achievable quality benchmarks.[1]

The proposed biological mechanism of MSC-derived exosomes differs from PRP at a fundamental level. Rather than delivering a concentrated burst of growth factors, exosomes deliver a complex cargo of proteins, lipids, messenger RNAs, and microRNAs that may influence gene expression and cellular signaling in recipient cells. This distinction is not cosmetic: the downstream biology of these two mechanisms is meaningfully different, and the research questions surrounding each are different as a result.

A 2025 review in Pharmaceutics notes that the cellular source of exosomes determines their cargo composition, and that MSC-derived exosomes from different tissue sources (bone marrow, adipose, umbilical cord) carry distinct profiles that may be relevant to specific research applications.[2]

A Factual Comparison

The table below compares key characteristics of MSC-derived exosomes and PRP across dimensions relevant to clinical procurement and practice. No clinical efficacy claims are made in this comparison.

This comparison is descriptive, not evaluative. Whether either product is appropriate in a given clinical context is a decision that belongs entirely to the licensed practitioner, informed by the specific protocol, patient population, and current regulatory requirements.

What the Research Says About Each

PRP has a longer published literature than exosomes. Studies examining PRP in orthopedic, hair, wound care, and aesthetic contexts span more than two decades. However, this body of literature is complicated by the same variability problem described above: preparation protocols, platelet concentrations, activation methods, and patient populations differ substantially across studies, making meta-analytic conclusions difficult. Several systematic reviews have found insufficient homogeneity in PRP research to draw strong efficacy conclusions for specific indications, even with many individual positive studies in the literature.

MSC-derived exosome research is growing rapidly but is earlier in development. A 2025 analysis in the Journal of Pharmacology and Pharmacotherapeutics identified more than 90 registered human clinical trials involving exosomes, with therapeutic applications representing approximately 21% of that total. The majority of completed human trials are Phase 1 or Phase 2, with early safety and feasibility endpoints. Phase 3 trials with defined primary efficacy endpoints are limited.[4]

A 2024 review in Clinical and Experimental Medicine examined the therapeutic research profile of MSC-derived exosomes specifically, focusing on tissue repair and inflammatory modulation applications. The authors identified a consistent mechanistic rationale across multiple preclinical studies and noted that early human trial data supports further investigation, while acknowledging that standardization of exosome preparation and dosing remains an open research question.[4b]

The honest summary for both products: promising research exists, standardization challenges remain, and large-scale Phase 3 efficacy data is limited. That is not a reason to dismiss either, but it is an important framing for honest clinical communication.

Practical Procurement Differences

For practices evaluating both options, the procurement realities are meaningfully different.

Some practices incorporate both into their offering. PRP preparation kits and MSC-derived exosomes serve different logistical and biological roles, and they are not mutually exclusive procurement decisions. ExaVeyra supplies closed-system PRP kits and cGMP MSC-derived exosomes to NPI-verified practices nationwide.

The Regulatory Picture for Each

Understanding the regulatory status of both products is a non-negotiable part of responsible clinical procurement. The following is a factual description of the current regulatory landscape, not legal advice.

PRP is generally regulated under 21 CFR Part 1271 as a human cell, tissue, and cellular and tissue-based product (HCT/P) when it meets the criteria for minimal manipulation and homologous use in a same-day procedure. PRP preparation devices, including centrifuges and disposable kits, may hold FDA 510(k) clearance as medical devices. PRP is not an FDA-approved drug, and practitioners should not make drug-like efficacy claims when using or marketing PRP services.

MSC-derived exosomes present a more complex regulatory profile. They are generally classified as biologics under Section 351 of the Public Health Service Act. Products intended for injection into human patients are unlikely to qualify for the minimal manipulation or homologous use exemptions that apply to some autologous HCT/Ps. There are no FDA-approved exosome products for general clinical use in the United States as of the date of this article. The FDA has issued warning letters to companies marketing exosome products with unapproved therapeutic claims. Practitioners using exosome products in clinical protocols should consult qualified regulatory and legal counsel before doing so.

For practitioners in B2B procurement, the relevant question is whether the supplier sources from FDA-registered facilities and provides full quality documentation. Our explainer on 503A vs 503B compounding covers the facility registration landscape in more detail.

What Practitioners Should Take Away

PRP and MSC-derived exosomes are biologically distinct products with different mechanisms, different regulatory histories, and different practical requirements. Neither is a replacement for the other, and neither is appropriate to market with unsupported therapeutic claims.

PRP is an autologous, growth-factor-rich preparation with a long clinical track record and a familiar regulatory pathway. Its variability is both a practical challenge and, in some contexts, a feature: it reflects the patient's own biology.

MSC-derived exosomes are a newer class of allogeneic biologic with a rapidly expanding research base. Their lot-controlled consistency is an advantage from a quality documentation standpoint. Their regulatory pathway requires careful attention, and practitioners should not incorporate them into clinical use without appropriate regulatory guidance.

Both are active areas of scientific investigation. Both carry research interest that is scientifically legitimate. Neither has the large-scale Phase 3 evidence base that would support broad clinical efficacy claims. Responsible practitioners communicate this accurately to patients and design protocols within the bounds of current regulatory requirements.